26th Nov 2020 17:02
(Alliance News) - The head of British drug manufacturer AstraZeneca PLC said on Thursday further research was needed on its Covid-19 vaccine after questions emerged over the protection it could offer.
"Now that we've found what looks like a better efficacy we have to validate this, so we need to do an additional study," Chief Executive Pascal Soriot told Bloomberg in an interview.
Shares in the FTSE 100-listed drug maker ended 0.7% lower at 7,748.00 pence in London on Thursday.
source: AFP
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca